ANXA5 and neoplasm: Compared to those in TC-1 tumor-bearing, cisplatin and AnxA5-E7 treated mice, combination treatment of cisplatin, AnxA5-E7, and additional immune checkpoint inhibitor generated significantly stronger E7-specific CD8+ T cell response in TC-1 tumor-bearing mice (Fig. 7d).